Výsledky vyhledávání

Akademický článek

Netakimab — new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-tosevere plaque psoriasis

Autor: A. A. Kubanov, A. L. Bakulev, A. V. Samtsov, V. R. Khairutdinov, E. V. Sokolovskiy, M. M. Kokhan, A. V. Artemyeva, E V. Chernyaeva, R. A. Ivanov

Publikováno v: Vestnik Dermatologii i Venerologii, Vol 95, Iss 2, Pp 15-28 (2019)

Netakimab, the original monoclonal antibody against IL-17A, is an innovative drug for the treatment of moderate-to-severe plaque psoriasis in patients who have indications for systemic therapy or phototherapy. Netakimab was approved in Russian Federa

Externí odkaz: https://doaj.org/article/4007b553226b4cd19f7d282f1ce493c9

Zobrazit plný text záznamu

Akademický článek

Efficacy and Safety of BCD-085, a Novel Interleukin-17 Inhibitor. Results of Phase II Clinical Trial in Patients with Moderate-to-Severe Plaque Psoriasis

Autor: A. V. Samtsov, V. R. Khairutdinov, A. L. Bakulev, A. A. Kubanov, A. E. Karamova, A. V. Artem’eva, T. V. Korotaeva

Publikováno v: Vestnik Dermatologii i Venerologii, Vol 0, Iss 5, Pp 52-63 (2018)

Recent studies on psoriasis confirmed that interleukin-17 (IL-17) plays a crucial role in the progression of the disease. Inhibition of this cytokine leads to significant improvement in the course of the disease. Russian biotechnology company BIOCAD

Externí odkaz: https://doaj.org/article/ad95b195b540473996348322541ef657

Zobrazit plný text záznamu

Akademický článek

Secukinumab efficacy and safety in indian patients with moderate-to-severe plaque psoriasis: Sub-analysis from FIXTURE, a randomized, placebo-controlled, phase 3 study

Autor: Ramesh M Bhat, B Leelavathy, Sacchidanand S Aradhya, Maragondanahalli G Gopal, D. V. S. Pratap, Mir Mubashir, Putta Srinivas, Sushil Y Pande, Amit S Thavkar

Publikováno v: Indian Dermatology Online Journal, Vol 8, Iss 1, Pp 16-24 (2017)

Title: Secukinumab efficacy and safety in Indian patients with moderate-to-severe plaque psoriasis: sub-analysis from FIXTURE (Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoria

Externí odkaz: https://doaj.org/article/51ef87121bc840a99021f0262f362125

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Safety and Efficacy of Itolizumab in the Treatment of Psoriasis: A Case Series of 20 Patients

Autor: Anchala Parthasaradhi

Publikováno v: Journal of Clinical and Diagnostic Research, Vol 10, Iss 11, Pp WD01-WD03 (2016)

Psoriasis is a common, chronic, relapsing/remitting, immune-mediated skin disease that causes itchy skin with silvery scales. It is characterized by thickened red erythematous plaques covered with silvery scales. Biological therapies have been recen

Externí odkaz: https://doaj.org/article/8f8701ee8e8c44998f2c94b86b2858f5

Zobrazit plný text záznamu

Dissertation/ Thesis

Effektivitet av sekukinumab vid behandling av medelsvår och svår plack-psoriasis : En litteraturstudie

Autor: Soligor, Olena

Introduktion: Psoriasis är en kronisk inflammatorisk systemsjukdom som drabbar främst hud och leder. På grund av mycket snabbt tillväxt av hudceller ger psoriasis utslag på huden. En av de vanligaste typerna av psoriasis är plack-psoriasis som

Externí odkaz: http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-114228

Zobrazit plný text záznamu

Efficacy of secukinumab in the treatment of moderate and severe plaque psoriasis

Autor: Soligor, Olena

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______681::c957974022b1e82bde51cb7d0fccdebc
http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-114228

Zobrazit plný text záznamu

Psoriasis Severity, Comorbidities, and Treatment Response Differ among Geographic Regions in the United States

Autor: Clinton W. Enos, Ryan W. Harrison, Robert R. McLean, Katie A O'Connell, Blessing Dube, Abby S. Van Voorhees

Publikováno v: JID Innovations, Vol 1, Iss 2, Pp 100025-(2021)
JID Innovations

Little is known about how psoriatic disease characteristics and treatment outcomes differ geographically in the United States. Our aim was to explore real-world, geographic variations in the use of biologic classes and outcomes within the Corrona Pso

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7272d941ba96bfc72feb8bbaed2b425d
http://www.sciencedirect.com/science/article/pii/S2667026721000254

Zobrazit plný text záznamu

Efficacy and Safety of BCD-085, a Novel Interleukin-17 Inhibitor. Results of Phase II Clinical Trial in Patients with Moderate-to-Severe Plaque Psoriasis

Autor: T. V. Korotaeva, A. E. Karamova, V. R. Khairutdinov, Alexey Samtsov, A. L. Bakulev, Antonina V. Artemeva, Alexey A. Kubanov

Publikováno v: Vestnik Dermatologii i Venerologii, Vol 0, Iss 5, Pp 52-63 (2018)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee1090fdf2e0b6eb85d0c846d1935d00
https://www.vestnikdv.ru/jour/article/view/344

Zobrazit plný text záznamu

Among the brightest antipsoriatic stars

Autor: Kamran Ghoreschi, K. Meier

Publikováno v: British Journal of Dermatology. 183:201-202

The COVID-19 pandemic has resulted in significant changes to working practices across the medical profession globally We undertook a study into the impact on dermatology trainees in the U K - a cohort that has been uniquely affected vs colleagues in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8da267a491f8999c8fbefbd7d4f09f2
https://doi.org/10.1111/bjd.18867

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání